secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001193125-24-021850
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase signs $5.66M ATM equity distribution agreement with H.C. Wainwright
------------------------------------------------------------------------------

- Entered into ATM equity offering agreement with H.C. Wainwright for up to $5,659,255 of common stock.
- Agent receives 3.0% commission on gross proceeds; company reimburses up to $50k initial legal fees plus $2.5k quarterly.
- Sales made under existing effective S-3 shelf registration statement (File No. 333-262551) at market prices.
- Company has no obligation to sell shares and may suspend or terminate the agreement at any time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/0001193125-24-021850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312524021850/d769675d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-021850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer